Leaping forward: how China’s biotech evolution is capturing the in vivo CAR-T frontier

“Ultimately, the goal remains consistent: addressing large unmet medical needs through whatever combination of global and local capabilities proves most effective.”

Yu (Clay) Cao, Vice President, Global Head of Drug Discovery, GenEditBio and Guest Editor of Cell & Gene Therapy Insights’ February edition speaks with Zhenghong Gao, Co-founder and COO of Uni-Pioneers Bio-Med, Inc., who examines the rise of in vivo CAR-T as a transformative modality within China’s rapidly evolving biotech ecosystem. The discussion highlights structural differences and complementarities between Chinese and Western innovation models, key technological and manufacturing challenges in delivery platforms, and the role of regulatory agility and evolving funding structures. Together, the conversation offers a forward-looking perspective on how global convergence may shape the next phase of gene and cell therapy innovation.

Please enter your email to access content Read now